OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2014.2583 ol-08-06-2790 Articles Gastric ulcer patients are more susceptible to developing gastric cancer compared with concomitant gastric and duodenal ulcer patients HONGJUN-BO1* ZUOWEI2* WANGAN-JIANG1 XUSHAN3 TULU-XIA3 CHENYOU-XIANG1 ZHUXUAN1 LUNONG-HUA1 Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China Correspondence to: Professor Nong-Hua Lu, Department of Gastroenterology, The First Affiliated Hospital of Nanchang University, 17 Yongwai Zheng Street, Nanchang, Jiangxi 330006, P.R. China, E-mail: allen2005066@sohu.com

Contributed equally

 12 2014 02 10 2014 8 6 2790 2794 28 02 2014 11 09 2014 Copyright © 2014, Spandidos Publications 2014 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.

Intestinal metaplasia (IM) and dysplasia are precancerous lesions of gastric cancer (GC); however, the prevalence of IM and dysplasia in patients exhibiting single gastric ulcer (GU) and concomitant gastric and duodenal ulcer (CGDU) varies. In the present study consecutive patients who had undergone esophagogastroduodenal endoscopy were retrospectively screened, and those presenting with GU or CGDU were further evaluated for IM and dysplasia. Patients diagnosed with GC or lymphoma and patients with a history of anti-Helicobacter pylori, non-steroidal anti-inflammatory medicine (NSAIM), H2-receptor antagonist or proton pump inhibitor therapy, were excluded from the present study. Of the 204,073 consecutively screened cases, 8,855 (4.3%) and 2,397 (1.2%) were diagnosed with GU and CGDU, respectively. A total of 1,722 GU and 233 CGDU patients were excluded; thus, 7,133 and 2,164 cases of GU and CGDU, respectively (n=9,297), were included in the present study. IM and dysplasia were observed in 1,348 (14.5%) and 210 (2.3%) patients, respectively. IM was more frequently identified in GU patients compared with CGDU patients (16.4 vs. 8.3%; odds ratio [OR], 2.158; 95% confidence interval [CI], 1.830–2.545; χ2=86.932; P<0.001); furthermore, GU patients exhibited significantly more frequent IM compared with CGDU patients at the gastric antrum (14.2 vs. 5.5%; OR, 2.818; 95% CI, 2.199–3.610; χ2=72.299; P<0.001), gastric incisura (24.0 vs. 14.1%; OR, 1.922; 95% CI, 1.502–2.432; χ2=30.402; P<0.001) and gastric corpus (12.6 vs. 3.3%; OR, 4.259; 95% CI, 1.030–17.609; χ2=4.736; P=0.026). Dysplasia was significantly more frequently identified in GU patients compared with CGDU patients (2.7 vs. 0.7%; OR, 4.027; 95% CI, 2.376–6.823; χ2=31.315; P<0.001), with GU patients exhibiting significantly more severe dysplasia at the gastric antrum (2.4 vs. 0.7%; OR, 3.339; 95% CI, 1.735–6.425; χ2=14.652; P<0.001) and the gastric incisura (2.9 vs. 0.7%; OR, 4.255; 95% CI, 1.694–10.689; χ2=11.229; P<0.001). Additionally, mild IM was more frequently identified in GU patients compared with CGDU patients (15.2 vs. 7.1%; OR, 2.353; 95% CI, 1.972–2.807; χ2=94.798; P<0.001) and dysplasia of a mild (1.7 vs. 0.6%; OR, 2.807; 95% CI, 1.580–4.987; χ2=13.519; P<0.001) or moderate/severe grade (1.1 vs. 0.09%; OR, 11.642; 95% CI, 2.857–47.439; χ2=18.896; P<0.001) was more frequent in GU patients compared with CGDU patients. IM and dysplasia were more frequently observed in GU compared with CGDU patients in the present study, which may be associated with an increased probability of developing GC.

 concomitant gastric and duodenal ulcers gastric ulcer intestinal metaplasia dysplasia gastric cancer Introduction

Gastric cancer (GC) is one of the leading causes of cancer-related mortality globally, and is the second and fourth most commonly diagnosed cancer in males and females in China, respectively (1,2). Intestinal-type GC develops via a well-defined cascade of precursors: Inflammation, atrophy, intestinal metaplasia (IM), dysplasia and, finally, carcinoma (3). It has been demonstrated that within five years of diagnosis of these precursors, the annual incidence of GC is 0.1, 0.25, 0.6, and 6.0% in atrophic gastritis, IM, mild-to-moderate dysplasia and severe dysplasia patients, respectively (4). Patients exhibiting IM are considered to be at a significantly elevated risk of developing GC (5,6); GC was identified to develop >10.9 times more frequently in the presence of IM compared with in the absence of IM (7). In addition, severe dysplasia patients exhibit a propensity to coexist with or progress to adenocarcinoma (8). These findings indicate that IM and dysplasia are precancerous lesions of GC (9), and may be important markers of the development of GC.

Gastric ulcer (GU) and duodenal ulcer (DU) are types of peptic ulcer disease (PUD). Previous studies have indicated that GU is a precancerous condition of GC (10), that a history of GU confers an increased risk of GC (11), that IM is commonly identified in GU patients (12), and that low- and high-grade dysplasia may develop into adenocarcinoma (13), thus, cases of IM and dysplasia in the presence of GU should be investigated. Furthermore, the risk of non-cardia GC decreased by half in DU patients that had not undergone surgery when compared with DU patients who had received surgery, whilst the risk of non-cardia GC doubled in GU patients that did not undergo surgery compared with GU patients who had received surgery (14). The long-term risk of GC development among patients exhibiting DU was identified to be significantly lower than in patients exhibiting GU (15). Furthermore, an inverse association was identified between the rate of GC and DU incidence (16,17). These findings indicate that DU may be an important protective factor against GC; however, to date, the underlying mechanisms remain unclear. Certain studies have revealed that DU is associated with a reduced risk of histological progression in IM and have identified DU as an independent protective factor against IM progression (18,19). However, the association between DU and dysplasia has not been well reported.

Concomitant gastric and duodenal ulcer (CGDU) disease is a type of PUD characterized by the coexistence of GU and DU. However, the prevalence of IM and dysplasia in CGDU patients and the differences between the histological alterations in GU and CGDU have not yet been elucidated using large cohort studies.

Therefore, the aim of the present study was to determine the underlying mechanisms associated with the incidence of GC in patients with GU and CGDU by demonstrating disparities in the prevalence of IM and dysplasia in GU and CGDU patients.

 Patients and methods Inclusion and exclusion criteria

Screening of consecutive patients who underwent esophagogastroduodenal endoscopy due to upper gastrointestinal symptoms at the First Affiliated Hospital of Nanchang University (Nanchang, China) between January 2002 and August 2011 was undertaken. Those who were diagnosed with GU or CGDU were recruited for further analysis. The present study was approved by the Ethics Committee of Nanchang University and informed consent was obtained from each patient.

Endoscopy was used to identify ulcers in the stomach and duodenum; active stage ulcers were identified by a mucosal break (diameter, ≥5 mm) (20) and by evidence of scarring or deformity. GU was diagnosed by the presence of ulcers in the stomach (between the cardia and the pylorus) and CGDU was diagnosed by the presence of ulcers in the stomach and duodenum regardless of complications (for example, gastrointestinal bleeding and perforation). Patients with a history of anti-Helicobacter pylori therapy, or treatment with non-steroidal anti-inflammatory medicines (NSAIMs) during the previous three months and H2-receptor antagonists or proton pump inhibitors during the previous four weeks, were excluded from the present study. The present study also excluded patients with a histologically determined diagnosis of GC or lymphoma.

Since a number of patients underwent more than one endoscopy during the investigation period, the index endoscopy was defined as the initial endoscopy. However, when a patient exhibited CGDU/GU and/or IM/dysplasia the index endoscopy was defined as the first endoscopy at which CGDU/GU and/or IM/dysplasia was diagnosed. Therefore, each patient was represented by a single index endoscopy (21).

 Histological examinations

During endoscopic examination, biopsies were obtained from ulcer-free regions of the stomach (gastric antrum, n=2; gastric body, n=2; incisura angularis, n=1) and the periphery of each ulcer (n≥2). Histological examinations were performed by pathologists at the First Affiliated Hospital of Nanchang University, and the Sydney System (22) was used to determine histological changes, including chronic and active inflammation, lymphoid aggregates or follicles, atrophy and, particularly, IM, dysplasia and grading (22).

 Statistical analysis

The data are presented as the mean ± standard deviation, a percentage or a rate. The χ2 test or Fisher’s exact test with odds ratio (OR) and 95% confidence interval (CI) were used to determine differences in the categorical variables. All statistical analyses were performed using the Statistical Package for the Social Sciences version 17 (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference and all reported P-values were two-tailed.

 Results Patients

Out of 204,073 consecutive cases, 8,855 (4.3%) and 2,397 (1.2%) were diagnosed with GU and CGDU, respectively. Of the 8,855 GU patients, 1,722 patients were excluded due to GC (n=697) or lymphoma (n=32) diagnosis, a history of anti-H. pylori therapy (n=257) and treatment with NSAIMs, H2-receptor antagonists or proton pump inhibitors (n=736). In addition, of the 2,397 CGDU patients, 233 were excluded due to GC diagnosis (n=11), a history of anti-H. pylori therapy (n=43) and treatment with NSAIMs, H2-receptor antagonists or proton pump inhibitors (n=179; Table I). Thus, 9,297 cases (GU, 7133 and CGDU, 2,164; male, 6,775 and female, 2,522; mean age, 45.8±12.1 years) were included in the present study (Table II).

 Prevalence of IM at various sites in GU and CGDU patients

Histological examination diagnosed IM in 1,348 patients (overall prevalence, 14.5%; Table II). The incidence rate (IR) of IM was significantly higher in GU patients compared with in CGDU patients (16.4 vs. 8.3%; OR, 2.158; 95% CI, 1.830–2.545; χ2=86.932; P<0.001). Furthermore, compared with CGDU patients, GU patients exhibited a significantly higher frequency of IM at the gastric antrum (14.2 vs. 5.5%; OR, 2.818; 95% CI, 2.199–3.610; χ2=72.299; P<0.001), gastric incisura (24.0 vs. 14.1%; OR, 1.922; 95% CI, 1.502–2.432; χ2=30.402; P<0.001) and gastric corpus (12.6 vs. 3.3%; OR, 4.259; 95% CI, 1.030–17.609; χ2=4.736; P=0.026). However, no difference in the prevalence of IM was identified between GU and CGDU patients at the gastric corpus, fundus or cardia (Table III).

 Prevalence of dysplasia at various sites in GU and CGDU patients

Dysplasia was detected in 210 patients (overall prevalence 2.3%; Table I). The IR of dysplasia was significantly higher in GU patients compared with in CGDU patients (2.7 vs. 0.7%; OR, 4.027; 95% CI, 2.376–6.823; χ2=31.315; P<0.001). Furthermore, compared with CGDU patients, GU patients exhibited a significantly higher frequency of dysplasia at the gastric antrum (2.4 vs. 0.7%; OR, 3.339; 95% CI, 1.735–6.425; χ2=14.652; P<0.001) and incisura (2.9 vs. 0.7%; OR, 4.255; 95% CI, 1.694–10.689; χ2=11.229; P<0.001). However, no difference in the prevalence of dysplasia was identified between GU and CGDU patients at the gastric corpus, fundus or cardia (Table IV).

 Grading of IM and dysplasia in GU and CGDU patients

Mild IM was more frequently detected in GU compared with CGDU patients (15.2 vs. 7.1%; OR, 2.353; 95% CI, 1.972–2.807; χ2=94.798; P<0.001); however, no difference was identified in patients with moderate/severe IM (1.2 vs. 1.2%; OR, 0.950; 95% CI, 0.614–1.468; χ2=0.054; P=0.822). The frequency of mild (1.7 vs. 0.6%; OR, 2.807; 95% CI, 1.580–4.987; χ2=13.519; P<0.001) or moderate/severe (1.1 vs. 0.09%; OR, 11.642; 95% CI, 2.857–47.439; χ2=18.896; P<0.001) dysplasia was significantly higher in GU compared with CGDU patients (Table V).

 Discussion

The present study demonstrated that IM and dysplasia were present in 14.5 and 2.3% of patients, respectively. The prevalence of IM and dysplasia in GU patients was significantly higher compared with CGDU patients, indicating that GU patients were more likely to develop GC, whilst the IR of GC may decline in DU patients.

The prevalence of IM and dysplasia in PUD patients has not been well investigated, although it has been identified that in Hong Kong the overall prevalence of IM was 9.4%, with 13.9 and 5.9% of H. pylori-positive and H. pylori-negative patients, respectively, exhibiting IM (23). Additionally, IM was identified at the highest frequency in GU patients (12). In the present study, the prevalence of IM/dysplasia was 16.4/2.7% and 8.3/0.7% in patients with GU and CGDU, respectively [overall prevalence (all patients), 14.5/2.3%].

A previous study identified that GC developed in 32 (3.3%) GU patients and three (0.68%) DU patients (15) and the frequency with which GC and DU coexisted was 0.1–1.7% (24), indicating that DU is associated to a lesser extent with GC. However, the underlying mechanisms of the low IR of GC in DU patients and the difference in pathological features between GU patients with or without DU remain unclear. Previously, DU has been associated with a reduced risk of histological progression and was identified as an independent protective factor against IM progression (18,19). In the present study, the prevalence of IM was significantly higher in GU patients compared with in CGDU patients, particularly for mild IM. Furthermore, IM was more frequently detected in GU patients at the gastric antrum, incisura and corpus. These findings indicate that GU was more likely to be associated with IM than CGDU, which may contribute to the high incidence of GC in GU patients.

Gastric dysplasia represents the penultimate stage of the gastric carcinogenesis sequence, and is thus a direct neoplastic precancerous lesion (12,25,26). In patients undergoing esophagogastroduodenal endoscopy in the Netherlands, 8% exhibited mild-to-moderate dysplasia and 0.6% exhibited severe dysplasia (4). The risk of gastric tumorigenesis increases with the severity of dysplasia (27) and previous studies have indicated that dysplasia of all grades requires further investigation. However, dysplasia has not been investigated sufficiently in patients with GU and CGDU. Thus, the current study demonstrated that the IR of dysplasia of all grades was significantly higher in GU patients compared with CGDU patients, and that the majority of dysplasia was detected in GU patients at the gastric antrum and incisura. The findings of the present study further demonstrate that dysplasia occurs more frequently in GU patients; thus, GU may increase the risk of gastric carcinogenesis.

A limitation of the present study was that sub-analyses for the subtypes of IM (complete vs. incomplete IM) were not performed, although incomplete IM has previously been proposed as a risk factor for GC development (9). Furthermore, various risk factors of GC (for example, H. pylori and diet) were not investigated in the present study and no regular follow-up of the patients occurred, preventing insight into the long-term histological consequences (i.e., dysplasia and GC) of the GU and CGDU patients exhibiting IM/dysplasia. Therefore, the clinical significance of the disparities in historical alterations between GU and CGDU patients requires verification in long-term prospective studies.

In conclusion, IM and dysplasia were present in 14.5 and 2.3% of patients, respectively. IM and dysplasia were significantly more prevalent in GU patients compared with CGDU patients, indicating that GU patients were more prone to developing GC compared with CGDU patients due to the low incidence of IM and dysplasia. Further long-term prospective investigations are required to verify these findings.

 Acknowledgements

The authors would like to thank the endoscopists and pathologists at the First Affiliated Hospital of Nanchang University (Nanchang, China) for their technical expertise and assistance in completing the study. The present study was supported by grants from the Natural Science Foundation of Jiangxi Province (grant no. 20122BAB215010). The authors would also like to thank the American Journal Experts (Durham, USA) for assisting in the preparation of the manuscript.

 References DanaeiGVander HoornSLopezADMurrayCJEzzatiMComparative Risk Assessment collaborating group (Cancers)Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factorsLancet366178417932005 SiegelRMaJZouZJemalACancer statistics, 2014CA Cancer J Clin649292014 CorreaPHaenszelWCuelloCTannenbaumSArcherMA model for gastric cancer epidemiologyLancet258601975 de VriesACvan GriekenNCLoomanCWCasparieMKde VriesEMeijerGAKuipersEJGastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the NetherlandsGastroenterology1349459522008 UemuraNOkamotoSYamamotoSMatsumuraNYamaguchiSYamakidoMTaniyamaKSasakiNSchlemperRJHelicobacter pylori infection and the development of gastric cancerN Engl J Med3457847892001 NaylorGMGotodaTDixonMShimodaTGattaLOwenRTompkinsDAxonAWhy does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patientsGut55154515522006 KimNParkRYChoSILimSHLeeKHLeeWKangHMLeeHSJungHCSongISHelicobacter pylori infection and development of gastric cancer in Korea: long-term follow-upJ Clin Gastroenterol424484542008 CloustonADTimely topic: Premalignant lesions associated with adenocarcinoma of the upper gastrointestinal tractPathology332712772001 Dinis-RibeiroMAreiaMde VriesACMarcos-PintoRMonteiro-SoaresMO’ConnorAPereiraCPimentel-NunesPCorreiaREnsariAEuropean Society of Gastrointestinal Endoscopy; European Helicobacter Study Group; European Society of Pathology; Sociedade Portuguesa de Endoscopia Digestiva: Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)Endoscopy4474942012 LvSXGanJHWangCCLuoEPHuangXPXieYHuangYBiopsy from the base of gastric ulcer may find gastric cancer earlierMed Hypotheses762492502011 MolloyRMSonnenbergARelation between gastric cancer and previous peptic ulcer diseaseGut402472521997 EidtSStolteMPrevalence of intestinal metaplasia in Helicobacter pylori gastritisScand J Gastroenterol296076101994 RuggeMCassaroMDi MarioFLeoGLeandroGRussoVMPennelliGFarinatiFInterdisciplinary Group on Gastric Epithelial Dysplasia (IGGED)The long term outcome of gastric non-invasive neoplasiaGut52111111162003 BahmanyarSYeWDickmanPWNyrénOLong-term risk of gastric cancer by subsite in operated and unoperated patients hospitalized for peptic ulcerAm J Gastroenterol102118511912007 OguraMYamajiYHikibaYMaedaSMatsumuraMOkanoKSassaRYoshidaHKawabeTOmataMGastric cancer among peptic ulcer patients: retrospective, long-term follow-upDig Liver Dis388118142006 WongBCChingCKLamSKLiZLChenBWLiYNLiuHJLiuJBWangBEYuanSZDifferential north to south gastric cancer-duodenal ulcer gradient in ChinaChina Ulcer Study GroupJ Gastroenterol Hepatol13105010571998 ChenMJWuDCKoYCChiouYYPersonal history and family history as a predictor of gastric cardiac adenocarcinoma risk: a case-control study in TaiwanAm J Gastroenterol99125012572004 LeungWKLinSRChingJYToKFNgEKChanFKLauJYSungJJFactors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradicationGut53124412492004 ChangCHWuMSChangYTChangMCShunCTLiuCYLinJTRisk factors for intestinal metaplasia in adult residents of Matzu: a cross-sectional studyJ Formos Med Assoc1018358402002 MalfertheinerPChanFKMcCollKEPeptic ulcer diseaseLancet374144914612009 XiaHHWongBCWongKWWongSYWongWMLaiKCHuWHChanCKLamSKClinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective studyAliment Pharmacol Ther15187518822001 DixonMFGentaRMYardleyJHCorreaPClassification and grading of gastritis. The updated Sydney System International Workshop on the Histopathology of Gastritis, Houston 1994Am J Surg Pathol20116111811996 YeeYKWongKWHuiCKChanCKChanAOLamSKFungFMHungIWongBCPrevalence and time trend of intestinal metaplasia in Hong KongJ Gastroenterol Hepatol248968992009 UbukataHNagataHTabuchiTKonishiSKasugaTTabuchiTWhy is the coexistence of gastric cancer and duodenal ulcer rare? Examination of factors related to both gastric cancer and duodenal ulcerGastric Cancer144122011 MisdrajiJLauwersGYGastric epithelial dysplasiaSemin Diagn Pathol1920302002 CorreaPClinical implications of recent developments in gastric cancer pathology and epidemiologySemin Oncol122101985 YouWCLiJYBlotWJChangYSJinMLGailMHZhangLLiuWDMaJLHuYREvolution of precancerous lesions in a rural Chinese population at high risk of gastric cancerInt J Cancer836156191999

Exclusion criteria.

Patients, n
Criterion GU CGDU
Gastric cancer 697 11
Lymphoma 32 0
History of anti-H. pylori therapy 257 43
Treatment with NSAIMs, H2-receptor antagonists or proton pump inhibitors 736 179

GU, gastric ulcer; CGDU, concomitant gastric and duodenal ulcer; H. pylori, Helicobacter pylori; NSAIMs, non-steroidal anti-inflammatory medicines.

Patient characteristics.

Variable Patients, n (%)
Disease
 Gastric ulcer 7133 (76.7)
 Concomitant gastric and duodenal ulcer 2164 (23.3)
Gender
 Male 6775 (72.9)
 Female 2522 (27.1)
Intestinal metaplasia 1348 (14.5)
Dysplasia 210 (2.3)

Mean age, 45.8±12.1 years; n=9,297.

Prevalence of IM at various gastric sites in GU and CGDU patients.

GU, n (%) CGDU, n (%)
Gastric site IM No IM IM No IM Odds ratio (95% CI) P-value
Antrum 563 (14.2) 3410 (85.8) 76 (5.5) 1297 (94.5) 2.818 (2.199–3.610) <0.001
Incisura 442 (24.0) 1402 (76.0) 102 (14.1) 622 (85.9) 1.922 (1.502–2.432) <0.001
Corpus 151 (12.6) 1046 (87.4) 2 (3.3) 59 (96.7) 4.259 (1.030–17.609) 0.026
Fundus 4 (6.3) 59 (93.7) 0 (0.0) 5 (100) 0.937 (0.878–0.999) 1.000
Cardia 8 (14.3) 48 (85.7) 0 (0.0) 1 (100) 0.857 (0.770–0.954) 1.000
Total 1168 (16.4) 5965 (83.6) 180 (8.3) 1984 (91.7) 2.158 (1.830–2.545) <0.001

IM, intestinal metaplasia; GU, gastric ulcer; CGDU, concomitant gastric and duodenal ulcer; n, number of patients; CI, confidence interval. P<0.05 was considered to indicate a statistically significant difference.

Prevalence of dysplasia at various gastric sites in GU and CGDU patients.

GU, n (%) CGDU, n (%)
Gastric site Dysplasia No dysplasia Dysplasia No dysplasia Odds ratio (95% CI) P-value
Antrum 95 (2.4) 3878 (97.6) 10 (0.7) 1363 (99.3) 3.339 (1.735–6.425) <0.001
Incisura 53 (2.9) 1791 (97.1) 5 (0.7) 719 (99.3) 4.255 (1.694–10.689) 0.001
Corpus 44 (3.7) 1153 (96.3) 0 (0.0) 61 (100) 0.963 (0.953–0.974) 0.268
Fundus 1 (1.6) 62 (98.4) 0 (0.0) 5 (100) 0.984 (0.954–1.105) 1.000
Cardia 2 (3.6) 54 (96.4) 0 (0.0) 1 (100) 0.964 (0.917–1.104) 0.965
Total 195 (2.7) 6938 (97.3) 15 (0.7) 2149 (99.3) 4.027 (2.376–6.823) <0.001

GU, gastric ulcer; CGDU, concomitant gastric and duodenal ulcer; CI, confidence interval. P<0.05 was considered to indicate a statistically significant difference.

IM and dysplasia grading in GU (n=7,133) and CGDU (n=2,164) patients.

IM, n (%) Dysplasia, n (%)
Grade GU CGDU Odds ratio (95% CI) P-value GU CGDU Odds ratio (95% CI) P-value
Mild 1083 (15.2) 153 (7.1) 2.353 (1.972–2.807) <0.001 119 (1.7) 13 (0.6) 2.807 (1.580–4.987) <0.001
Moderate/severe 85 (1.2)a 27 (1.2)b 0.950 (0.614–1.468) 0.822 76 (1.1)c 2 (0.09)d 11.642 (2.857–47.439) <0.001

Including

six cases of severe IM;

three cases of severe IM;

47 cases of severe dysplasia; and

one case of severe dysplasia.

IM, intestinal metaplasia; GU, gastric ulcer; CGDU, concomitant gastric and duodenal ulcer; n, number of patients; CI, confidence interval.